13-Year-Old Becomes World’s First to Trial Revolutionary Epilepsy Treatment
By Alabidun Shuaib AbdulRahman
A 13-year-old boy named Oran Knowlson from Somerset has become the first patient in the world to trial a revolutionary neurostimulator device embedded in his skull to manage severe epilepsy, Excel Magazine International can report.
According to reports, this groundbreaking technology has dramatically reduced his daytime seizures by 80%, transforming his quality of life.
Oran’s mother, Justine, expressed her joy to the BBC, noting that her son is now much happier and enjoys a significantly better quality of life.
Before the surgery, Oran’s life was dominated by his epilepsy, with Justine describing it as robbing him of his childhood.
Oran, who also has autism and ADHD, developed Lennox-Gastaut syndrome at age three, leading to numerous daily seizures.
Excel Magazine International reports that the first surgery took place in October 2023 at Great Ormond Street Hospital in London. The procedure was part of the CADET project, a series of trials assessing the safety and effectiveness of deep brain stimulation for severe epilepsy.
The surgery involved placing two electrodes deep into Oran’s brain, targeting the thalamus. These electrodes are connected to a neurostimulator embedded in his skull, designed to emit constant electrical pulses to disrupt abnormal brain activity that triggers seizures.
Since the device was activated, Oran has shown remarkable improvement. He no longer experiences daytime drop seizures and has more manageable night-time seizures.
Justine observed that Oran is more alert and engaged, with significant improvements in his overall condition. The device is recharged wirelessly daily, allowing Oran to continue with activities he enjoys, such as watching TV and even taking riding lessons.
Oran’s success story marks a promising step forward in epilepsy treatment. The trial will extend to three more children with Lennox-Gastaut syndrome. Future advancements may include the neurostimulator responding in real-time to brain activity changes, potentially blocking seizures before they happen.
Consultant paediatric neurosurgeon Martin Tisdall, who led the surgery, emphasized the potential of this new treatment to significantly reduce complications compared to traditional methods.
He expressed delight over the positive impact on Oran’s life and remains hopeful about the treatment’s future applications.
Justine Knowlson is optimistic about the future, expressing gratitude to the medical team at Great Ormond Street Hospital. While acknowledging that the treatment is not a cure, she is hopeful that Oran will continue to improve and regain more of his childhood, a sentiment echoed by the whole family.
